CSS
CGEM icon

Cubist Systematic Strategies’s Cullinan Oncology CGEM Stock Holding History

Cubist Systematic Strategies’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.32M Buy
+222,318
New +$1.63M 0.01% 1812
2025
Q1 		– Sell
-130,647
Closed -$1.59M – 2926
2024
Q4 		$1.59M Buy
+130,647
New +$1.88M 0.01% 1521
2024
Q2 		– Sell
-55,888
Closed -$952K – 3094
2024
Q1 		$952K Sell
55,888
-1,038
-2% -$16K 0.01% 2212
2023
Q4 		$580K Buy
56,926
+24,294
+74% +$215K ﹤0.01% 2442
2023
Q3 		$295K Buy
32,632
+26,584
+440% +$277K ﹤0.01% 2604
2023
Q2 		$65.1K Buy
+6,048
New +$64.2K ﹤0.01% 3061
2022
Q4 		– Sell
-14,015
Closed -$180K – 4279
2022
Q3 		$180K Sell
14,015
-92,675
-87% -$1.25M ﹤0.01% 3820
2022
Q2 		$1.37M Buy
106,690
+91,164
+587% +$1.03M 0.01% 2200
2022
Q1 		$163K Buy
15,526
+3,610
+30% +$48.8K ﹤0.01% 3104
2021
Q4 		$184K Buy
+11,916
New +$238K ﹤0.01% 3058

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Cubist Systematic Strategies's CGEM Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Cullinan Oncology (CGEM) in Q3 2025: 222,318 shares worth $1.32M. The stake represents 0.01% of the portfolio and ranks #1812 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in CGEM as recently as Q4 2024.

Cubist Systematic Strategies first reported a position in CGEM in Q4 2021 and has held it in 10 quarters since. The position peaked at $1.59M in Q4 2024. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

  • Cubist Systematic Strategies held 222,318 shares of Cullinan Oncology worth $1.32M as of Q3 2025.
  • Cullinan Oncology was a new Cubist Systematic Strategies position in Q3 2025.
  • Cullinan Oncology made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1812 holding.
  • Cubist Systematic Strategies first reported a position in Cullinan Oncology in Q4 2021 and has held it in 10 quarters since.
  • Cubist Systematic Strategies's Cullinan Oncology position peaked at $1.59M in Q4 2024.
  • 145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.